Back

Stromal Gasdermin D-mediated Pyroptosis Drives Maladaptive CD4⁺ T-cell Remodeling in Tet2-Deficient Hematopoiesis

Ji, P.; Ren, K.; Han, X.; Li, E.; Wang, P.; Bi, H.; Cai, W.; Aydemir, I.; Wai, C. M.; Niu, H.; Yang, J.; Liu, Y.; Vadasz, B.; Sukhanova, M.; Fang, D.; Cui, W.

2026-05-05 cancer biology
10.64898/2026.05.01.722102 bioRxiv
Show abstract

An inflammatory bone marrow microenvironment is increasingly recognized as critical in myeloid disease evolution, yet how stromal inflammation interfaces with adaptive immunity remains poorly defined. Here, we show that stromal pyroptosis drives mutation-specific myeloid expansion by coordinating monocytic remodeling and CD4 T-cell activation. Genetic ablation of gasdermin D in the bone marrow stroma suppressed stromal pyroptosis and attenuated Tet2-deficient myeloid expansion. Tet2 deficiency skewed monocyte and macrophage differentiation toward an activated, antigen-presenting state that interacted with pyroptotic stromal cells to promote expansion of a distinct CD4 T-cell population. These cells expressed canonical T follicular helper markers (Bcl6, Cxcr5, Il21, and Cd40l) together with interferon-responsive and tissue-interaction programs, consistent with an inflammation-adapted TFH-like state. CD40L produced by these cells reinforced the expansion of Tet2-deficient monocytes and macrophages, establishing a feed-forward stromal-immune circuit. Disruption of this axis through stromal gasdermin D deficiency or CD40L blockade attenuated myeloid expansion in vivo. Consistent with these findings, patients with isolated TET2 loss-of-function mutations exhibited CD4 T-cell skewing and CD40L+ T-cell-rich tertiary lymphoid structures in the bone marrow. Together, these data identify a pyroptosis-dependent stromal-immune axis that links early myeloid inflammation to maladaptive remodeling of adaptive immunity and reveals a context-dependent therapeutic vulnerability in Tet2-deficient hematopoiesis.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature
575 papers in training set
Top 2%
14.0%
2
Cancer Discovery
61 papers in training set
Top 0.1%
9.6%
3
Nature Cell Biology
99 papers in training set
Top 0.4%
8.0%
4
Science
429 papers in training set
Top 4%
6.8%
5
Journal of Experimental Medicine
106 papers in training set
Top 0.5%
6.0%
6
Blood
67 papers in training set
Top 0.3%
6.0%
50% of probability mass above
7
Nature Communications
4913 papers in training set
Top 35%
4.6%
8
Journal of Clinical Investigation
164 papers in training set
Top 0.7%
4.1%
9
Developmental Cell
168 papers in training set
Top 5%
3.8%
10
Cell Reports
1338 papers in training set
Top 14%
3.7%
11
Molecular Cell
308 papers in training set
Top 4%
3.7%
12
Immunity
58 papers in training set
Top 2%
3.4%
13
Cell Stem Cell
57 papers in training set
Top 0.7%
2.9%
14
Nature Cancer
35 papers in training set
Top 0.4%
2.6%
15
Science Translational Medicine
111 papers in training set
Top 3%
1.6%
16
Cancer Research
116 papers in training set
Top 3%
1.2%
17
Cell
370 papers in training set
Top 14%
1.2%
18
eLife
5422 papers in training set
Top 50%
1.2%
19
Science Advances
1098 papers in training set
Top 25%
1.1%
20
Cell Genomics
162 papers in training set
Top 5%
0.9%
21
Nature Genetics
240 papers in training set
Top 7%
0.9%
22
The EMBO Journal
267 papers in training set
Top 6%
0.7%
23
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 47%
0.7%
24
Cancer Cell
38 papers in training set
Top 2%
0.6%
25
Leukemia
39 papers in training set
Top 0.9%
0.6%
26
Cell Reports Medicine
140 papers in training set
Top 10%
0.6%
27
Nature Medicine
117 papers in training set
Top 6%
0.6%
28
Genes & Development
90 papers in training set
Top 2%
0.6%